The Skin Cytoimmunogram: From Cell Suspension to a Characteristic of the Skin State
How a skin cytoimmunogram is obtained and what information it provides for describing the skin state
The skin cytoimmunogram presents the results of a study of a cell suspension obtained from a biopsy specimen of a selected skin site: which cell subpopulations were found, with which markers and in what numbers. In Russian it is abbreviated ЦИГК; the English version of this site uses the full term. In the author’s model, the skin cytoimmunogram is a tool for measuring individual components of the skin state S(x, t). This article explains how the result is obtained, how the report form is structured and how to read its numbers.
Quotations from the author’s works and the wording of the report form are given in translation from Russian; the originals are in the Russian version of the article.
What task does the skin cytoimmunogram perform in the theory?
The method described in patent RU 2 630 607 C1 is aimed at “determining the subpopulation composition of skin cells and obtaining a skin cytoimmunogram”; its technical result is “determination of the phenotype of skin cells and of the number of skin cells of a certain phenotype.”
The author emphasizes that Phenotypic Dermatology is, first and foremost, a theory of skin states and transitions between them, and the skin cytoimmunogram is one of the tools for its experimental implementation. In the model of the skin state S(x, t), the skin cytoimmunogram is “a tool for measuring individual components of S(x, t).”
Three meanings: the method, the cytoimmunogram, the interpretation
In this article, these words are used in three different meanings (the author’s clarification, agreed on 20–21 November 2026):
- The method for obtaining a skin cytoimmunogram — the sequence of obtaining, preparing and examining the material.
- The cytoimmunogram — the presentation of the results of the study, including phenotypes and quantitative indicators.
- The interpretation of the skin cytoimmunogram — a conclusion that links the results to the research question and clinical data.
How is the result obtained?
The sequence is described in patent RU 2 630 607 C1 and in the monograph:
- Collection of a skin biopsy specimen from the selected site — a small fragment of skin taken by punch biopsy.
- Preparation of a cell suspension — homogenization of the tissue, filtration and centrifugation.
- Determination of cell viability by flow cytometry with the 7-AAD dye. The authors explain: “If the viability of skin cells is not determined, the results obtained will be less accurate, since some cells are destroyed.”
- Labelling — incubation of the cells with fluorochrome-conjugated monoclonal antibodies (labelled with fluorescent dyes).
- Phenotyping by flow cytometry using a set of CD markers — determination of the phenotypes of cell subpopulations.
- Determination of the number of cells of each phenotype — the results are entered in the “Skin cytoimmunogram” report form.
Procedure parameters and differences between descriptions of the method
Parameters according to patent RU 2 630 607 C1 (claims and example): collection of a skin biopsy specimen to a depth of 2 mm; homogenization in 0.9 % aqueous sodium chloride solution at +23…+25 °C; filtration of the homogenate through an inert filter partition with a pore diameter of 20 µm; centrifugation at 400 g for 5 minutes at +23…+25 °C; determination of viability (7-AAD; side scatter and fluorescence in channel 3, FL3); incubation for 20 minutes protected from light; markers CD3, CD4, CD8, CD14, CD16, CD19, CD34, CD44, CD45, CD49, CD54, CD63, CD80, CD146, CD203c, CD207, CD249.
The monograph (pp. 39–44): 2 mm punch; homogenization for 30 seconds at +23 °C; to exclude particles that do not correspond to living cells in size and granularity, gates were set on forward scatter, side scatter and CD45; “At least 10⁶ cells were analysed in each sample.”
Differences between descriptions:
- biopsy depth — 2 mm (the 2017 patent); “punch biopsy 1–2 mm in diameter to a depth of up to 5 mm” (the article in Kosmetika i meditsina [Cosmetics and Medicine], 2017); 1.5…3.0 mm without capturing subcutaneous fat (the 2026 patent for the method for determining FIVK);
- the set of markers “is determined by the task set for the given study”; the FIVK patent does not include the CD203c marker.
Sources: patents RU 2 630 607 C1 and RU 2 870 371 C1; the monograph, pp. 39–44; articles of 2017 and 2018 (see “Sources”).
What does a cytoimmunogram look like? Breakdown of the report form
A medical report form, “Skin cytoimmunogram”, was developed for recording the results. Below it is broken down into parts using the blank form from the monograph (Figure 17, p. 44); the row names are translated from Russian, and the marker notation is kept as on the form.
1. Study details (upper part of the form): “SKIN CYTOIMMUNOGRAM No.___”, “dated ‘___’ ____ 20___”, “Full name”, “Age”.
2. Cell groups and indicators (middle part). Each row has two fields: “Relative, %” and “Absolute, cells/ml”. In the training example, only the keratinocyte rows are filled in (illustrative values; see the calculation below).
| Row of the form | Relative, % | Absolute, cells/ml | The percentage is calculated from… |
|---|---|---|---|
| Keratinocytes CD49f+, | 20 | 200,000 | all cells of the sample |
| of which activated CD49f+ HLA-DR+ | 10 | 20,000 | CD49f+ keratinocytes |
| Fibroblasts (fibrocytes) CD45- CD14- CD44+, | all cells of the sample | ||
| of which activated CD45- CD14- CD44+ CD80+ | fibroblasts | ||
| Mast cells CD249+, | all cells of the sample | ||
| of which activated CD249+ CD63+ | mast cells | ||
| Monocytes (macrophages) CD45+ CD14+, | all cells of the sample | ||
| of which activated CD45+ CD14+ HLA-DR+ | monocytes (macrophages) | ||
| Intraepidermal macrophages CD 207+, | all cells of the sample | ||
| of which activated CD 207+ CD80+ | intraepidermal macrophages | ||
| CD 207+ HLA-DR+ | intraepidermal macrophages | ||
| CD 207+ CD80+ HLA-DR+ | intraepidermal macrophages | ||
| Endothelial cells CD146+, | all cells of the sample | ||
| of which activated CD146+ CD34+ | endothelial cells | ||
| CD146+ HLA-DR+ | endothelial cells | ||
| CD146+ CD54+ | endothelial cells | ||
| CD146+ CD54+ HLA-DR+ | endothelial cells | ||
| Lymphocyte populations: T lymphocytes CD45+ CD3+ | all cells of the sample | ||
| T helper cells CD45+ CD3+ CD4+ CD8- | |||
| T suppressor cells CD45+ CD3+ CD4- CD8+ | |||
| B lymphocytes CD45+ CD3- CD19+ | all cells of the sample | ||
| NK lymphocytes CD45+ CD3- CD16+ CD56+ | all cells of the sample |
Table. Rows of the “Skin cytoimmunogram” report form (the monograph, Figure 17; row names translated from Russian) and the denominator of the percentages according to the author’s explanation (21 November 2026). The values in the keratinocyte rows are illustrative training values, not patient data.
Note the change of denominator: the percentage of a main population is calculated from all cells of the sample, while the percentage in an “of which activated” row is calculated from its parent population.
3. Conclusion and examiner (lower part of the form): “The results of the study indicate”, “For the physician”, “Analysis performed by”.
Cell viability is a separate indicator of the study.
How should the quantitative data be read?
The author explained the calculation rules as follows (21 November 2026):
- The percentage of a main population is calculated from the total number of all cells in the particular sample.
- The percentage in an “of which activated” row is calculated from the corresponding parent population. For example, CD49f+HLA-DR+ is calculated from CD49f+ keratinocytes.
- Absolute values refer to one millilitre of the suspension of the particular sample and are calculated from the total concentration and the corresponding proportions.
- Cell viability is a separate indicator.
Formulas for the absolute values:
N population = N × p / 100
N activated = N × p / 100 × a / 100
where N is the total cell concentration in the suspension (cells/ml); p is the percentage of the main population among all cells; a is the percentage of activated cells in the parent population.
Sample suitability criterion. According to the author’s explanation, samples are considered reliably significant at a total concentration of at least 1 million cells/ml. The threshold refers to all cells of the sample obtained after punch biopsy (the author’s criterion, explanation of 21 November 2026).
Training calculation
An illustrative example: the values are invented for training purposes and are not patient data.
- Total cell concentration in the suspension: N = 1,000,000 cells/ml.
- CD49f+ keratinocytes — p = 20 % of all cells: 1,000,000 × 20 / 100 = 200,000 cells/ml.
- Of which activated CD49f+HLA-DR+ — a = 10 % of keratinocytes: 1,000,000 × 20 / 100 × 10 / 100 = 20,000 cells/ml.
- Proportion of activated keratinocytes among all cells of the sample: 20,000 / 1,000,000 × 100 = 2 % (the same as 20 % × 10 % = 2 %).
These illustrative values are the ones entered in the keratinocyte rows in the breakdown of the form above.
How does one move from measurement to interpretation?
What is measured directly is the number of cells with a particular set of markers and cell viability. Conclusions about the functional state and about cell interactions are drawn by the researcher on the basis of these data. The author emphasizes the need to distinguish between direct measurements and conclusions about interactions drawn from phenotypic data.
The interpretation links the results to the research question and clinical data. In the author’s words, the skin cytoimmunogram does not replace the diagnosis but complements it with objective data on the state of the cellular microenvironment.
How should observations be compared?
The result refers to a specific skin site and time point of the study — x and t in the notation S(x, t). The method for comparing states adopted on this site starts from this: specify the skin site studied and the time point of observation, describe the characteristics and, at a repeat observation, compare them.
Comparability is affected by the conditions under which the material is obtained and stored. An example is the study in the 2018 article: skin biopsy specimens from the gluteal region of 64 people (four groups of 16 people by sex and age: 25–45 and 45–65 years) were examined first native and then after cryopreservation. The table gives the proportions of cells in per cent in the format “value ± deviation” (“±” means “within the deviation” — the author’s explanation). For example, activated CD49f+HLA-DR+ keratinocytes: 3.25 ± 0.75 % in the native sample and 1.3 ± 0.04 % in the thawed sample; the mark *** denotes significance of the difference at p < 0.001.
The authors concluded: “When comparing the percentage ratios of skin cells in the two samples, no substantial discrepancy in the indicators was found, except for cells expressing HLA-DR antigens and adhesion molecules on their surface, that is, antigen-presenting cells.” This conclusion refers to the conditions of that study. Questions about the reproducibility of measurements are collected on the page Open Research Questions.
What are the limits of the description?
- In the author’s words, the skin cytoimmunogram does not directly measure all components of the conceptual model of the skin state; the author links this caveat to the question of how intercellular interactions and tissue organization can be measured by flow cytometry.
- The study requires a skin biopsy specimen. The author regards this as a limitation “of the method of obtaining data, not… of the concept of phenotypic analysis itself.”
- The set of markers is limited by the research task.
How is it related to FIVK?
A calculated indicator has been built from the phenotyping indicators — the phenotypic index of skin inflammation (FIVK, the Latin transliteration of the Russian abbreviation ФИВК); how it is calculated is explained in the article FIVK: Calculating and Interpreting the Inflammatory Component of the Skin State. The method for determining it (patent RU 2 870 371 C1) uses 11 phenotypes of skin cells; the patent names the method for obtaining a skin cytoimmunogram as the closest analogue.
Continue reading
- Skin State: From Cellular Phenotype to a Mathematical Model — what the skin state S(x, t) is, how it can be written down and how it differs from a diagnosis.
- The Skin Cell Subpopulation Phenotype — the Unit of Investigation — what exactly is distinguished at the cellular level: the cell, the subpopulation, the phenotype and two levels of description.
- FIVK: Calculating and Interpreting the Inflammatory Component of the Skin State — how the index is calculated from 11 phenotypes and how its value should be understood.
See also: the term “Skin cytoimmunogram” · overview of methods · principle 4
Sources
Published sources
- Goltsov S. V. Sposob opredeleniya fenotipicheskogo indeksa vospaleniya kozhi [Method for determining the phenotypic index of skin inflammation; our translation]. Patent RU 2 870 371 C1, IPC G01N 33/53. Application 2026101577 of 22.01.2026; published 21.09.2026, Bull. No. 27 (in Russian). — description of the invention: prototype — method RU 2 630 607 · Patents · Original
- Goltsov S. Fenotipicheskaya dermatologiya [Phenotypic Dermatology]. Tyumen: Publisher S. V. Goltsov, 2026. 208 p. ISBN 978-5-600-04919-2 (in Russian). — pp. 39–45; the report form — Figure 17, p. 44 · About the monograph · Original
- Goltsov S. V. Dermatologiya: ot nablyudeniya k ponimaniyu [Dermatology: from observation to understanding]. The author’s blog, goltsovs.ru (in Russian). — “Criticism”: answers to remarks No. 10 and No. 12 · Original
- Goltsov S. V., Goltsova E. N., Sukhovey Yu. G., Kostolomova E. G., Pauls V. Yu. Tsitoimmunogramma kozhi kak sposob otsenki ee immunnogo statusa [Skin cytoimmunogram as a way to assess its immune status]. Kosmetika i meditsina [Cosmetics and Medicine]. 2017; (3): 48–50 (in Russian). — pp. 48–49: steps for obtaining a skin cytoimmunogram · Entry in Publications
- Goltsov S. V., Goltsova E. N., Sukhovey Yu. G., Kostolomova E. G., Pauls V. Yu. Cytoimmunogram of the skin: a new method for objective evaluation of the skin cell subpopulation profile [official English title of the journal article]. Medical Immunology (Russia). 2018; 20(3): 373–382. doi: 10.15789/1563-0625-2018-3-373-382 (article in Russian). — “Materials and methods”; Table 1 (p. 379) and “Second observation” (pp. 377, 380) · Entry in Publications · Original
- Goltsov S. V., Kostolomova E. G., Sukhovey Yu. G., Pauls V. Yu. Sposob opredeleniya subpopulyatsionnogo sostava kletok kozhi i polucheniya tsitoimmunogrammy kozhi [A method for determining the subpopulation composition of skin cells and obtaining a skin cytoimmunogram]. Patent RU 2 630 607 C1. Application 2016121997 of 02.06.2016; registered and published 11.09.2017 (in Russian). — description, example and claims · Patents · Original
The author’s clarifications and materials
- Goltsov S. V. Explanations of the notation S(x, t): a formal model of the skin state, notation of a transition, the role of the skin cytoimmunogram and FIVK, definition of diagnosis (author’s statement, PDF, 2026-11-18; in Russian). — the author’s explanations of 18 November 2026: the skin cytoimmunogram as a tool for measuring individual components of S(x, t)
- Goltsov S. V. Scientific review of the article “What is the skin state S(x, t)” (author’s statement, 2026-11-18; in Russian). — the author’s review of 18 November 2026: direct measurements and conclusions about interactions
- Goltsov S. V. Agreed clarifications for the articles on the skin cell subpopulation phenotype, the skin cytoimmunogram and FIVK (author’s statements, 2026-11-20 and 2026-11-21; in Russian). — the author’s explanations of 20–21 November 2026: three meanings; rules for calculating percentages and absolute values; the 1 million cells/ml criterion; the “±” sign
This material is for information only and does not replace a consultation with a doctor.